Share prices for Shine Holdings Inc. (OTCBB: SHDG ) skyrocketed more than 80 percent after market open today, vaulting from 40 cents a share to 65 cents a share in less than an hour.The source of this influx of investor interest seems to be the company’s latest word on its super-oxygenation product, which passed the latest round of testing with flying colors.
According to Shine Holdings CEO Brett Swailes, the company’s patented device works by “smashing” water in a high-pressurized cylinder. The output of this process are bubbles no bigger than 5 microns in size – too small to be seen by the naked eye – which super-oxygenates the water. Naturally, this device is perfect for America’s growing aquaculture industry, as well as for wastewater cleaning businesses and even biodefense purposes, where gases such as ozone are diffused into water as a way of examining anthrax.
“Oxygenation is really critical to the fishing industry,” Swailes told Market News First. “Traditionally, the way the fish farming industry has going about oxygenating their water through big fountain aerators, which wastes a lot of electricity.[Our system] is so efficient it’s ridiculous. It’s basically done inside a vessel – we’ve got the product patented, and we’ve had it in fabrication for months and it just came through.”
“In fish farming you have ponds, and the fish are highly sensitive to decreased levels of oxygen in the water, which comes about from the actual respiration of the animals,” Swailes continued. “The fish go nuts when they encounter this super-oxygenated water. It leads to vastly reduced times to finish the crop fish. It’s been a win-win situation for us as a company profitably.”
In fact, Swailes is so proud – and so confident – of his company’s success in creating a viable, unique product that he’s posted pictures of the device in action on his company’s Web site, www.shine-holdings.com/pictures.htm.
And he’s not the only one. According to reports, Shine Holdings has executed a formal letter of intent to license its technology to U.S. BioDefense Inc., a Department of Defense Central Contractor developing homeland security and leading-edge biotechnologies. Under the agreement, U.S. BioDefense expects to secure an exclusive licensing agreement from Shine Holdings for an annual fee of $100,000.
“Ozone is very powerful, and is used to kill certain bacteria and agents such as anthrax … and the various viral hemorrhagic fevers,” Swailes said. “This enables them to do that. We’re going to start testing with ozone in the future.”
For more information, visit http://www.shine-holdings.com/.
